are that renal disease also activates the renin-angiotensin system, sympathetic drive is high, and the glomeruli overgrow and fibrose, resembling the terminally failing heart. Thus the next round of renal trials may need, besides an ACE inhibitor or ARB and very large numbers, new modifications to lessen mortality. Speculations could include spironolactone… (More)
Figures and Tables
Sorry, we couldn't extract any figures or tables for this paper.